Safety and Efficacy of Zonisamide in Patients with Epilepsy: A Post-Marketing Surveillance Study
Hye Jin Lee, Jeong Min Son, Jihee Mun, Dong Wook Kim
J Epilepsy Res. 2015;5(2):89-95. Published online 2015 Dec 30 DOI: https://doi.org/10.14581/jer.15015
Citations to this article as recorded by 
The Effect of Zonisamide on Rat Bone Mass, Structure, and Metabolism
Iva Karesova, Julius Simko, Sona Fekete, Eva Zimcikova, Jana Malakova, Helena Zivna, Ladislava Pavlikova, Vladimir Palicka
Pharmacology.2023; 108(4): 359. CrossRef
Incidence rates of severe cutaneous adverse reactions due to antiseizure medication: A nationwide study using health claims data in Korea
Soo Jie Chung, Kyung‐Min Ahn, Ji Hyun Oh, Ji‐Su Shim, Heung‐Woo Park
Epilepsia.2021; 62(1): 250. CrossRef
Long‐term effects of zonisamide in adult patients with intellectual disability
Kattrinna Eck, Christophe Rauch, Frank Kerling, Hajo Hamer, Martin Winterholler
Acta Neurologica Scandinavica.2021; 144(3): 275. CrossRef
Adverse Cutaneous Drug Reactions Associated with Old- and New- Generation Antiepileptic Drugs Using the Japanese Pharmacovigilance Database
Keiko Hosohata, Ayaka Inada, Saki Oyama, Iku Niinomi, Tomohito Wakabayashi, Kazunori Iwanaga
Clinical Drug Investigation.2019; 39(4): 363. CrossRef
A retrospective analysis of using zonisamide and retention in monotherapy among patients with epilepsy in routine clinical practice
I. G. Rudakova, Yu. A. Belova, A. S. Kotov, M. V. Romanova
Zhurnal nevrologii i psikhiatrii im. S.S. Korsakov.2019; 119(11): 80. CrossRef
Stevens–Johnson syndrome/toxic epidermal necrolysis associated with zonisamide
Karina L. Vivar, Kimberly Mancl, Lucia Seminario‐Vidal
Clinical Case Reports.2018; 6(2): 258. CrossRef